Amber Therapeutics
PrivateLast Round
Series A
Jun 10, 2024
Total Funding Raised
$100M
Company Overview
Amber Therapeutics is a biotechnology company that develops innovative bioelectronic platforms for closed-loop therapies aimed at treating mixed urinary incontinence through targeted peripheral interventions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amber Therapeutics Comparables
Compare Amber Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Juniper Biomedical | 85% | |
| BlueWind Medical | 83% | |
| Neuspera Medical | 80% |
Amber Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 10, 2024 | ||||
| Seed | Jan 24, 2023 |
Amber Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Enterprise Associates | Series A |
| Lightstone Ventures | Series A |
| Oxford Science Enterprises | Series A, Seed |
| F-Prime Capital | Series A |
| UKRI Innovate UK | Seed |
| Intuitive Ventures | Series A |
| Oxford Science Enterprises | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Accelerating towards first Pivotal Trial for Picostim System.
- Jun 10, 2024
$100M round led by New Enterprise Associates (NEA)
Recent news
Latest coverage and updates
- is_developingAug 11, 2026
Amber Tx is developing closed-loop neuromodulation therapy system to treat mixed urinary incontinence on Aug 1st '26.
Amber Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Amber Therapeutics's valuation, stock price, and market status.
Is Amber Therapeutics a public or private company?
Amber Therapeutics is a private company.
What is the current stock price of Amber Therapeutics?
Amber Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Amber Therapeutics worth (valuation)?
Valuation information for Amber Therapeutics is not publicly available.
Can I buy Amber Therapeutics stock?
Amber Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Amber Therapeutics's last funding round?
Amber Therapeutics's most recent funding round was Series A on June 10, 2024.
Who are the main investors in Amber Therapeutics?
Key investors in Amber Therapeutics include New Enterprise Associates (NEA).
Will Amber Therapeutics IPO soon?
No public IPO plans have been announced for Amber Therapeutics.
How can I track Amber Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Amber Therapeutics's secondary market activity and sign up for updates.